Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Point of Care Test for Anemia Developed

By LabMedica International staff writers
Posted on 19 May 2015
New diagnostic technology may shift some hemoglobin testing for anemia out of clinical laboratories and into near-patient settings and it may also be possible to use this new diagnostic device for patient self-testing.

The new diagnostic test has many advantages over the conventional hematological tests done in clinics, hospital laboratories, and free-standing medical laboratories operating expensive laboratory analyzers as it requires no power source, and the results are available within one minute.

The new medical laboratory test is called AnemoCheck and was developed by scientists and students at Emory University (Atlanta, GA, USA), Children’s Healthcare of Atlanta (GA, USA) and the Georgia Institute of Technology (Atlanta, GA). More...
A startup company called Sanguina will create the market for this new test and will operate out of Atlanta (GA, USA).

Each AnemoCheck point-of-care test kit enables patients to check hemoglobin levels by simply pricking their finger to draw 5 μL of blood into a capillary tube, inserting that tube into a larger tube with a pre-filled chemical solution, mixing, waiting one minute, and assessing the color change of the solution using a reference color scale card included with the kit. The hemoglobin present in the blood acts as a catalyst for a reduction-oxidation reaction and within approximately 45 seconds, a color change occurs. Ideally, the test would be able to subjectively differentiate low, medium and high levels of hemoglobin to diagnose anemia at home.
The user compares the solution in the tube to the color-scale card that comes with the kit. The color ranges from green-blue to red depending on the severity of anemia. Readings can be sent to a Smartphone application (app) for interpretation, storage, and sharing. The test is very convenient as AnemoCheck eliminates the need for repeated trips to clinical laboratories for the chronically ill or for patients who must travel great distances to reach medical facilities.

Erika Tyburski, BS, who developed the AnemoCheck, said, “Results indicate that AnemoCheck can detect even the mildest form of anemia across many different etiologies with sensitivity of more than 90% and specificity of more than 79%. We are currently planning beta testing for home-validation in a sickle cell disease user group that will gauge the ease of use and likelihood of adoption within this group. We do not intend to replace clinical testing, but supplement it to offer piece of mind, and potentially screen for changes in hemoglobin prior to disease-specific crises.”

Related Links:

Emory University
Children’s Healthcare of Atlanta 
Georgia Institute of Technology 



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Hemodynamic System Monitor
OptoMonitor
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.